ACT was awarded
#3 in The University of Houston's Cougar 100 companies!
ACT's compound PFK-158 featured in CEO/CFO Magazine; Announces MD
Anderson and UT Health Science Center San Antonio added as
clinical trial sites. Click HERE to read more.
ACT's compound PFK-158 has been chosen
by Informa and Kantar Health as one of the "2014 Top 10 Most
Interesting Oncology Projects to Watch". Click HERE to read more.
ACT is currently
conducting a Phase I, open
label, dose escalation, multicener clinical trial
in patients with advanced solid tumors. The
study is to evaluate the safety, tolerability and
activity of PFK158,
molecule therapeutics candidate. The centers
invovled with the study are the Brown Cancer
Center at the University of Louisville and the
Lombardi Cancer Center at Georgetown
ACT presented a poster during the
2014 AACR Annual meeting, titled “Grich
DNA Genomic Sequences Derived from the Promoter Region of ProOncogenes
Inhibit Tumor Growth and Demonstrate Synergies”, that
highlighted the preclinical properties of oligonucleotides inhibiting cMyc, Bcl2,
Dr. Jason Chesney, Deputy Director, Brown Cancer Center, was invited to
make an oral presentation at the 2014 AACR annual meeting on PFK158.
The presentation, titled “Identification of a PFKFB3 inhibitor suitable for
phase I trial testing that synergizes with the BRaf
highlighted the preclinical characteristics of PFK158
and described its
synergy with BRAF inhibitors.
Advanced Cancer Therapeutics has moved to The Nucleus Building at
300 East Market Street, Suite 280,
Louisville, KY 40202.